AU2013345930B2 - 2-pyridone compound - Google Patents

2-pyridone compound Download PDF

Info

Publication number
AU2013345930B2
AU2013345930B2 AU2013345930A AU2013345930A AU2013345930B2 AU 2013345930 B2 AU2013345930 B2 AU 2013345930B2 AU 2013345930 A AU2013345930 A AU 2013345930A AU 2013345930 A AU2013345930 A AU 2013345930A AU 2013345930 B2 AU2013345930 B2 AU 2013345930B2
Authority
AU
Australia
Prior art keywords
compound
compounds
present
crystal
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013345930A
Other languages
English (en)
Other versions
AU2013345930A1 (en
Inventor
Hajime Asanuma
Masahiro Bohno
Tomomichi Chonan
Keiko Fusegi
Yudai Imai
Seishi Ishiyama
Shin Itoh
Takanori Kawaguchi
Shoichi Kuroda
Marie Mizutani
Souichi Monma
Takumi Okada
Hirofumi Ota
Shigetada Sasako
Nagaaki Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of AU2013345930A1 publication Critical patent/AU2013345930A1/en
Assigned to NISSAN CHEMICAL INDUSTRIES, LTD. reassignment NISSAN CHEMICAL INDUSTRIES, LTD. Request for Assignment Assignors: NISSAN CHEMICAL INDUSTRIES, LTD., TAISHO PHARMACEUTICAL CO., LTD.
Application granted granted Critical
Publication of AU2013345930B2 publication Critical patent/AU2013345930B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2013345930A 2012-11-13 2013-11-12 2-pyridone compound Ceased AU2013345930B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-249792 2012-11-13
JP2012249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 ２－ピリドン化合物

Publications (2)

Publication Number Publication Date
AU2013345930A1 AU2013345930A1 (en) 2015-06-04
AU2013345930B2 true AU2013345930B2 (en) 2017-08-24

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013345930A Ceased AU2013345930B2 (en) 2012-11-13 2013-11-12 2-pyridone compound

Country Status (25)

Country Link
US (1) US9695148B2 (enExample)
EP (1) EP2921489B1 (enExample)
JP (1) JP5963025B2 (enExample)
KR (1) KR102160841B1 (enExample)
CN (1) CN104768944B (enExample)
AU (1) AU2013345930B2 (enExample)
BR (1) BR112015010823A2 (enExample)
CA (1) CA2891406C (enExample)
DK (1) DK2921489T3 (enExample)
ES (1) ES2641469T3 (enExample)
HU (1) HUE034557T2 (enExample)
IL (1) IL238701B (enExample)
IN (1) IN2015DN03869A (enExample)
MX (1) MX361479B (enExample)
MY (1) MY173812A (enExample)
NO (1) NO2921489T3 (enExample)
NZ (1) NZ707832A (enExample)
PH (1) PH12015501056B1 (enExample)
PL (1) PL2921489T3 (enExample)
PT (1) PT2921489T (enExample)
RU (1) RU2662157C2 (enExample)
SG (1) SG11201503716RA (enExample)
TW (1) TWI591064B (enExample)
WO (1) WO2014077235A1 (enExample)
ZA (1) ZA201503323B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 ２−ピリドン化合物を含有する医薬
EP3144305A4 (en) * 2014-05-13 2017-12-27 Nissan Chemical Industries, Ltd. Method for producing 2-pyridone compound
LT3804714T (lt) * 2018-05-31 2025-03-10 Hua Medicine (Shanghai) Ltd. Farmacinis derinys ir kompozicija, ir derinio preparatas, kurio sudėtyje yra gliukokinazės aktyvatorius ir biguanido hipoglikeminis vaistas, taip pat jų gamybos būdas ir panaudojimas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011068211A1 (ja) * 2009-12-04 2011-06-09 大正製薬株式会社 ２－ピリドン化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
CZ301366B6 (cs) 1999-03-29 2010-02-03 F. Hoffmann-La Roche Ag 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
EP2076502B1 (en) 2006-06-08 2011-05-18 Eli Lilly And Company Substituted carboxamides as group i metabotropic receptor antagonists
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200904440A (en) * 2007-07-17 2009-02-01 Bristol Myers Squibb Co Method for modulating GPR119 G protein-coupled receptor and selected compounds
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
JP2013010750A (ja) * 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd ２−ピリドン化合物を含有する医薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011068211A1 (ja) * 2009-12-04 2011-06-09 大正製薬株式会社 ２－ピリドン化合物

Also Published As

Publication number Publication date
IL238701A0 (en) 2015-06-30
JPWO2014077235A1 (ja) 2017-01-05
AU2013345930A1 (en) 2015-06-04
RU2662157C2 (ru) 2018-07-24
EP2921489A4 (en) 2016-04-06
SG11201503716RA (en) 2015-06-29
MY173812A (en) 2020-02-24
MX361479B (es) 2018-12-06
PL2921489T3 (pl) 2018-01-31
CA2891406C (en) 2021-03-16
PT2921489T (pt) 2017-12-01
KR20150082301A (ko) 2015-07-15
CA2891406A1 (en) 2014-05-22
TWI591064B (zh) 2017-07-11
EP2921489B1 (en) 2017-09-06
ZA201503323B (en) 2016-08-31
HK1207856A1 (en) 2016-02-12
JP5963025B2 (ja) 2016-08-03
PH12015501056A1 (en) 2015-07-27
CN104768944A (zh) 2015-07-08
RU2015122717A (ru) 2017-01-10
US20160289208A1 (en) 2016-10-06
PH12015501056B1 (en) 2015-07-27
ES2641469T3 (es) 2017-11-10
DK2921489T3 (en) 2017-10-16
IN2015DN03869A (enExample) 2015-10-02
BR112015010823A2 (pt) 2017-07-11
NZ707832A (en) 2019-03-29
WO2014077235A1 (ja) 2014-05-22
EP2921489A1 (en) 2015-09-23
HUE034557T2 (en) 2018-02-28
CN104768944B (zh) 2017-03-29
KR102160841B1 (ko) 2020-09-28
MX2015005884A (es) 2015-12-09
NO2921489T3 (enExample) 2018-02-03
TW201434826A (zh) 2014-09-16
IL238701B (en) 2018-10-31
US9695148B2 (en) 2017-07-04

Similar Documents

Publication Publication Date Title
US12209081B2 (en) Heterocycle derivatives for treating TRPM3 mediated disorders
US20250270210A1 (en) BCL-2 Inhibitor
CN104822680B (zh) 咪唑并吡啶化合物
US11124494B2 (en) Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CZ361392A3 (en) Novel azaheterocyclylmethyl-chromans
US20230312557A1 (en) P2x3 modulators
KR102519948B1 (ko) 암 치료용 화합물 및 조성물
TWI829481B (zh) 雙環吲唑糖皮質素受體拮抗劑
EP2921489B1 (en) 2-pyridone compound
TW201236685A (en) New pyrazole amide derivatives
TW202515867A (zh) 17β-羥基類固醇脫氫酶13型之抑制劑及其使用方法
JP6048533B2 (ja) ２−ピリドン化合物を含有する医薬
CA2700936A1 (en) Production method for pyrazol-3-yl-benzamide derivative
TWI917480B (zh) 用於治療ｔｒｐｍ３介導病症之雜環衍生物
HK1207856B (en) 2-pyridone compound
EA050841B1 (ru) Гетероциклические производные для лечения расстройств, опосредованных trpm3
NZ717556B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NISSAN CHEMICAL INDUSTRIES, LTD.

Free format text: FORMER APPLICANT(S): NISSAN CHEMICAL INDUSTRIES, LTD.; TAISHO PHARMACEUTICAL CO., LTD.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired